OneChain Immunotherapeutics

About:

OCI develops therapies for leukaemia based on CAR–T.

Twitter/X: onechaintx

Top Investors: Invivo Capital Partners, Centre for the Development of Industrial Technology (CDTI), Nara Capital, Clave Capital, ICREA

Description:

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Total Funding Amount:

9.75M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Barcelona, Catalonia, Spain

Founded Date:

2020-01-01

Founders:

Pablo Menéndez

Number of Employees:

11-50

Last Funding Date:

2023-06-22

IPO Status:

Private

Industries: